Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:289 (2 August), doi:10.1136/bmj.327.7409.289-a
| The first 150 words of the full text of this article appear below. |
EDITORMacGillivray et al potentially make a huge contribution to the understanding of the relative utility of selective serotonin reuptake inhibitors and older antidepressants in the treatment of depression in primary care.1 However, the usefulness of their meta-analysis is limited by the original data, as is so often the case.
These results are very difficult to interpret, not least because the comparitors used in the key studies are pharmacologically heterogeneous. Two studies, including one of the key three crucial studies providing data in an unambiguous format, used mianserin as a comparitor. Mianserin is a tetracyclic, not a tricyclic as the paper's title might imply. It is not a potent reuptake inhibitor but a potent and thus sedative anti-histamine. A third study used lofepramine as a comparitor, a more modern tricyclic with a much more benign anticholinergic side effect profile than its older cousins, which have an adverse event rate
Anthony S Hale, professor of psychiatry
University of Kent, Canterbury CT2 7NZ A.S.Hale@ukc.ac.uk